Breaking News, Collaborations & Alliances

Autifony, Jazz Partner on Ion Channel Targets for Neurological Disorders

Autifony will lead drug discovery and preclinical development, Jazz will lead clinical development, mfg., regulatory activities, and commercialization.

Autifony Therapeutics, a company involved in the development of pharmaceuticals for rare CNS disorders and other serious brain diseases, has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc, for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

Autifony will lead drug discovery and preclinical development activities on the two targets. Subsequent to successful completion of such preclinical development, Jazz will lead all clinical development, manufacturing and regulatory activities and commercialization.

Autifony will receive an upfront payment from Jazz and is eligible to receive development, regulatory and commercial milestones across the two programs. Autifony is also eligible to receive royalties on future sales.

Charles Large, CEO of Autifony Therapeutics, said, “We are excited to be working with Jazz Pharmaceuticals on two novel ion channel targets, on which we can bring to bear Autifony’s long standing expertise in small molecule ion channel drug discovery and development. Jazz has an exceptional track record of rapidly advancing neuroscience development programmes and effectively commercializing novel therapies that offer improvements over current standards of care. These programmes have the potential to bring ground-breaking benefits to patients in a range of indications.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters